$1,318.00
This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, key upcoming and regulatory events, probability of success, patent information, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
8 Treatment of hypogonadism in females
8 Treatment of hypogonadism in males
9 EPIDEMIOLOGY
10 MARKETED DRUGS
14 PIPELINE DRUGS
18 RECENT EVENTS AND ANALYST OPINION
18 Multiple Drugs for Hypogonadism (June 25, 2019)
19 KEY UPCOMING EVENTS
20 KEY REGULATORY EVENTS
20 Reanalysis Of Existing Data Supports Lipocine Tlando Resubmission
21 PROBABILITY OF SUCCESS
22 REVENUE OPPORTUNITY
23 CLINICAL TRIAL LANDSCAPE
24 Sponsors by status
25 Sponsors by phase
27 BIBLIOGRAPHY
27 Prescription information
29 APPENDIX
LIST OF FIGURES
14 Figure 1: Overview of pipeline drugs for hypogonadism in the US
14 Figure 2: Pipeline drugs for hypogonadism, by company
15 Figure 3: Pipeline drugs for hypogonadism, by drug type
15 Figure 4: Pipeline drugs for hypogonadism, by classification
19 Figure 5: Key upcoming events in hypogonadism
21 Figure 6: Probability of success in the endocrine-other pipeline
23 Figure 7: Clinical trials in hypogonadism
23 Figure 8: Top 10 drugs for clinical trials in hypogonadism
24 Figure 9: Top 10 companies for clinical trials in hypogonadism
24 Figure 10: Trial locations in hypogonadism
25 Figure 11: Hypogonadism trials status
26 Figure 12: Hypogonadism trials sponsors, by phase
LIST OF TABLES
11 Table 1: Marketed drugs for hypogonadism
16 Table 2: Pipeline drugs for hypogonadism in the US
18 Table 3: Multiple Drugs for Hypogonadism (June 25, 2019)
22 Table 4: Historical global sales, by drug ($m), 2015–19
22 Table 5: Forecasted global sales, by drug ($m), 2020–24
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!